LEXICON PHARMACEUTICALS, INC. (LXRX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$67.1M
Cash & Equivalents
$14.7M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$986M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06217302 Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease PHASE3 Recruiting 150

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for LXRX.

SEC EDGAR Filings

All SEC filings for LEXICON PHARMACEUTICALS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.